Eledon Pharmaceuticals (ELDN) News Today $3.85 -0.03 (-0.77%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period HC Wainwright Reaffirms "Buy" Rating for Eledon Pharmaceuticals (NASDAQ:ELDN)HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Eledon Pharmaceuticals in a research note on Wednesday.November 20 at 8:38 AM | marketbeat.comCantor Fitzgerald Issues Positive Estimate for ELDN EarningsNovember 19 at 2:29 AM | americanbankingnews.comResearch Analysts Set Expectations for ELDN FY2024 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Equities researchers at Cantor Fitzgerald raised their FY2024 earnings per share estimates for Eledon Pharmaceuticals in a report released on Wednesday, November 13th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the compaNovember 18 at 2:30 AM | marketbeat.comEledon Pharmaceuticals: Strong Financials and Promising Clinical Developments Justify Buy RatingNovember 15, 2024 | markets.businessinsider.comFY2024 Earnings Forecast for ELDN Issued By Lifesci CapitalEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Analysts at Lifesci Capital lifted their FY2024 EPS estimates for shares of Eledon Pharmaceuticals in a report released on Wednesday, November 13th. Lifesci Capital analyst R. Katkhuda now expects that the company will post earnings per sNovember 15, 2024 | marketbeat.comEledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) market cap dropped US$48m last week; individual investors who hold 57% were hit as were institutionsNovember 14, 2024 | finance.yahoo.comEledon Pharmaceuticals Reports Strong Q3 2024 ResultsNovember 14, 2024 | markets.businessinsider.comEledon Pharmaceuticals price target lowered to $20.50 from $28 at LadenburgNovember 14, 2024 | markets.businessinsider.comEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deEledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial ResultsNovember 12, 2024 | globenewswire.comEledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation ConferenceNovember 6, 2024 | markets.businessinsider.comPromising Clinical Trials and Strong Financial Position Make Eledon Pharmaceuticals a Compelling InvestmentOctober 30, 2024 | markets.businessinsider.comNoble Financial Reaffirms Their Buy Rating on Eledon Pharmaceuticals (ELDN)October 30, 2024 | markets.businessinsider.comBuy Rating Justified for Eledon Pharmaceuticals Amid Promising Clinical Developments and Financial StabilityOctober 29, 2024 | markets.businessinsider.comEledon Pharmaceuticals prices 18.36M shares at $3.65 in underwritten offeringOctober 29, 2024 | markets.businessinsider.comEledon Pharmaceuticals Shares Hit 52-Week High After Positive Trial DataOctober 29, 2024 | marketwatch.comEledon: Changing Scope Of Immunosuppressive Drug Space With TegoprubartOctober 29, 2024 | seekingalpha.comEledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsOctober 29, 2024 | globenewswire.comEledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago MedicineOctober 29, 2024 | globenewswire.comEledon Pharma (NASDAQ:ELDN) Stock Quotes, Forecast and News SummaryOctober 2, 2024 | benzinga.comNantahala Capital Management LLC Invests $1.58 Million in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Nantahala Capital Management LLC purchased a new stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 600,000 shares of the company's stoOctober 1, 2024 | marketbeat.comEledon Pharmaceuticals’ Tegoprubart: A Strong Buy Based on Industry-Wide Validation and Promising Drug DataSeptember 24, 2024 | markets.businessinsider.comEledon Pharmaceuticals to Present at the Cantor Global Healthcare ConferenceSeptember 11, 2024 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Eledon Pharmaceuticals (ELDN), Opthea Limited Sponsored ADR (OPT)September 9, 2024 | markets.businessinsider.comEledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant PatientsSeptember 4, 2024 | globenewswire.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Expected to Earn Q3 2024 Earnings of ($0.20) Per ShareEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Equities researchers at Leerink Partnrs reduced their Q3 2024 earnings estimates for Eledon Pharmaceuticals in a research report issued on Tuesday, August 20th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($0.2August 23, 2024 | marketbeat.comBuy Rating Justified by Eledon Pharmaceuticals’ Strategic Progress and Growth PotentialAugust 22, 2024 | markets.businessinsider.comVanguard Group Inc. Buys 273,703 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Vanguard Group Inc. raised its stake in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 39.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 969,121 shares of the company's stock afteAugust 20, 2024 | marketbeat.com2 'Strong Buy'-Rated Stocks That Wall Street Believes Can Soar Over 360%August 19, 2024 | msn.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Down 16.1% in JulyEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) was the recipient of a large decline in short interest in July. As of July 31st, there was short interest totalling 108,100 shares, a decline of 16.1% from the July 15th total of 128,800 shares. Based on an average daily volume of 158,400 shares, the short-interest ratio is presently 0.7 days.August 16, 2024 | marketbeat.comEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating ResultsAugust 15, 2024 | finanznachrichten.deEledon Expects to Restate Results, Delays Quarterly ReportAugust 14, 2024 | marketwatch.comEledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating ResultsAugust 14, 2024 | globenewswire.comEledon Pharmaceuticals Inc (ELDN)August 10, 2024 | investing.comEledon Pharmaceuticals (NASDAQ:ELDN) Shares Down 1.7% Eledon Pharmaceuticals (NASDAQ:ELDN) Trading Down 1.7%August 2, 2024 | marketbeat.comEledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ RejectionJuly 29, 2024 | globenewswire.com2 Penny Stocks Wall Street Expects to Soar Over 400%July 22, 2024 | msn.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Sees Significant Growth in Short InterestEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) was the recipient of a significant growth in short interest during the month of June. As of June 30th, there was short interest totalling 170,600 shares, a growth of 225.6% from the June 15th total of 52,400 shares. Based on an average daily trading volume, of 203,700 shares, the days-to-cover ratio is currently 0.8 days.July 11, 2024 | marketbeat.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Up 7.4% in JuneEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) was the target of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 52,400 shares, a growth of 7.4% from the May 31st total of 48,800 shares. Based on an average daily trading volume, of 210,300 shares, the days-to-cover ratio is currently 0.2 days.July 2, 2024 | marketbeat.comEledon to Participate in the Leerink Partners Therapeutics Forum: I&I and MetabolismJuly 2, 2024 | globenewswire.comPenny Stock Picks: 3 Companies Poised to Graduate to the Big LeaguesJune 17, 2024 | investorplace.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Down 74.5% in MayEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) saw a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 48,800 shares, a decrease of 74.5% from the May 15th total of 191,500 shares. Based on an average daily volume of 200,600 shares, the short-interest ratio is presently 0.2 days.June 12, 2024 | marketbeat.com3 High-Potential Penny Stocks to Turn $1000 into $1 Million: June 2024June 11, 2024 | investorplace.comArmistice Capital LLC Purchases 365,000 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Armistice Capital LLC lifted its stake in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 20.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,189,000 shares of the company's stock after aJune 6, 2024 | marketbeat.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Expected to Post Q2 2024 Earnings of ($0.36) Per ShareEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Research analysts at Lifesci Capital issued their Q2 2024 EPS estimates for shares of Eledon Pharmaceuticals in a report issued on Tuesday, June 4th. Lifesci Capital analyst R. Katkhuda expects that the company will post earnings per sharJune 5, 2024 | marketbeat.comEledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationJune 3, 2024 | globenewswire.comEledon Pharmaceuticals’ Tegoprubart Shows Promising Trial Results and Fuels Buy RatingMay 10, 2024 | markets.businessinsider.comEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial ResultsMay 9, 2024 | finanznachrichten.deEledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial ResultsMay 9, 2024 | globenewswire.comEledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant CongressMay 9, 2024 | globenewswire.com Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run… All you have to do is follow this link here ELDN Media Mentions By Week ELDN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELDN News Sentiment▼0.540.45▲Average Medical News Sentiment ELDN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELDN Articles This Week▼131▲ELDN Articles Average Week Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies STOK News Today OCS News Today TRML News Today IMNM News Today IGMS News Today CDXC News Today ALT News Today GHRS News Today ABVX News Today HUMA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELDN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
